Just one day after filing a prospectus with the SEC for a registered underwritten public offering, Momenta Pharmaceuticals Inc. has priced the offering of 4 million shares of its common stock (NASDAQ:MNTA) at $14.35 per share. The proceeds, before expenses, to Momenta will be approximately $57.4 million. Read More
Some potential protein drug targets, such as transcription factors, are difficult to study well in a high-density screening situation. Many transcription factors flop around like wet noodles with little organized structure, and are regarded as "undruggable" by many pharma companies. Read More
• Bavarian Nordic AS, of Kvistgard, Denmark, reached a special protocol assessment agreement with the FDA for a Phase III registration study of Prostvac, an off-the-shelf therapeutic vaccine being developed under a cooperative research and development agreement with the National Cancer Institute, in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. Read More
• AltheaDx Inc., of San Diego, partnered with Compendia Bioscience Inc., of Ann Arbor, Mich., to jointly discover novel products and services in the area of cancer biomarkers. Read More
Cephalon Inc. is betting that its short-term $350 million investment in stem cell technology will help to plug a much more expensive hole with the April 2012 patent expiration of its sleep disorder drug Provigil. Read More
WASHINGTON – Investors in Orexigen Therapeutics Inc. Wednesday were not only bubbling over with excitement about an FDA panel's backing of the firm's obesity drug Contrave (naltrexone/bupropion) – with the company's stock rocketing as high as 129 percent – but shares of potential competitors Arena Pharmaceuticals Inc. and Vivus Inc. also were on fire, leaping as high as 20.5 percent and 19.5 percent, respectively. Read More
